Evidence map›Paper›PMID 41710855›Full record

ArticleCureus2026

Hepatic-Predominant Immunoglobulin G Lambda Light Chain Amyloidosis Associated With Multiple Myeloma: A Report of an Exceptionally Rare Case.

Guilherme Jesus, Inês Soares, Ana Sofia Silva, Mariana Baptista, Ana Gonçalves Ribeiro

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guilherme JesusInternal Medicine, Unidade Local de Saúde Gaia e Espinho, Vila Nova de Gaia, PRT.
Inês SoaresInternal Medicine, Unidade Local de Saúde Gaia e Espinho, Vila Nova de Gaia, PRT.
Ana Sofia SilvaInternal Medicine, Unidade Local de Saúde Gaia e Espinho, Vila Nova de Gaia, PRT.
Mariana BaptistaInternal Medicine, Unidade Local de Saúde Gaia e Espinho, Vila Nova de Gaia, PRT.
Ana Gonçalves RibeiroAnatomic Pathology, Unidade Local de Saúde Gaia e Espinho, Vila Nova de Gaia, PRT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloid light chain (AL) amyloidosis represents a rare plasma cell dyscrasia characterized by the deposition of misfolded immunoglobulin light chains in various organs. While hepatic involvement is often detected histologically in systemic AL amyloidosis, symptomatic hepatic presentation as the dominant initial manifestation remains uncommon. We present the case of a 65-year-old woman who developed progressive constitutional symptoms, cholestatic jaundice, and hepatomegaly as the initial manifestations of immunoglobulin G (IgG) lambda light chain amyloidosis associated with multiple myeloma. The patient presented with a six-month history of weight loss exceeding 20 kilograms, daily vomiting, night sweats, and progressive jaundice. Laboratory investigations revealed marked cholestasis, with an alkaline phosphatase level of 1252 U/L, a gamma-glutamyl transferase level of 1426 U/L, hyperbilirubinemia, and coagulopathy. Serum immunofixation electrophoresis demonstrated an IgG lambda monoclonal protein (M-protein). Abdominal fat pad biopsy confirmed lambda light chain amyloid deposition, while bone marrow examination revealed 30% plasma cell infiltration consistent with multiple myeloma. Echocardiography demonstrated findings suggestive of cardiac involvement with reduced global longitudinal strain and apical sparing pattern. Notably, renal function remained preserved without proteinuria, and skeletal imaging showed no lytic lesions. The patient was treated with daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (Dara-VCD), demonstrating a very good partial response (VGPR) with 75% reduction of M-protein (from 1.2 g/L to 0.3 g/L) after four treatment cycles. This case exemplifies a clinically significant presentation combining IgG lambda-type multiple myeloma, systemic AL amyloidosis, and dominant hepatic involvement as the initial clinical manifestation. The combination of these features is rarely reported in the medical literature, making this case instructive for recognizing atypical presentations that may lead to diagnostic delays. Early recognition and prompt initiation of plasma cell-directed therapy are essential for improving outcomes in this challenging condition.

Indexed as

amyloid light chain amyloidosisdaratumumabhepatic amyloidosismultiple myelomaplasma cell dyscrasia

Identifiers

PMID41710855
PMCPMC12910527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.